Navigation Links
Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching Commercialization
Date:9/5/2013

Rockville, Maryland (PRWEB) September 05, 2013

Fisher BioServices Inc., a leading provider of biorepository/biobanking and ultra cold chain logistics services, announced that Dan O’Donnell, Associate Director of Cell Therapy Logistics, will speak at three upcoming industry conferences. Mr. O’Donnell, who is widely known for his expertise on ultra cold chain distribution and regulatory compliance in transporting biologics and cryogenically frozen cell-based therapeutics, has been invited to present at the International Society for Cellular Therapy (ISCT) North America Regional Meeting in Philadelphia, Pennsylvania (September 8–11), the Stem Cell & Regenerative Medicine USA Congress in Cambridge, Massachusetts (September 30–October 1), and the ColdChainIQ 11th Annual GDP & Temperature Management Logistics Global Forum in Chicago, Illinois (September 30–October 4).

Mr. O’Donnell will share his expertise on the challenges of moving high value biologics at ultra cold temperatures from the manufacturer to the patient bedside—in clinical trials as well as in the commercial marketplace. This will include an overview of how product packaging and clinical trial design can complicate logistics, add expense, and limit the number of clinical sites available for conducting phase II and phase III clinical trials. He will use a case study format to illustrate the technical challenges of meeting FDA requirements while moving products around the world at cryogenic temperatures, and share his experience with both autologous and allogeneic cell-based therapies.

Industry professionals who’d like to learn more about the latest end-to-end cell therapy solutions from Fisher BioServices can register for Mr. O’Donnell’s webinar - “Ultra Cold Chain & Logistical Challenges in Cell Therapy Clinical and Commercial Development” on October 10th, 2013. As Fisher BioServices’ Associate Director of Cell Therapy Logistics, Mr. O’Donnell has worked with numerous clients and assisted them in designing and implementing their ultra cold chain strategies which include packaging, qualified shipping systems, and patient delivery mechanisms that are cost-effective and align with patient safety needs and FDA requirements. He brings extensive experience and insight to the process of commercialization and distribution of biological therapeutics. Mr. O’Donnell’s webinar will include his insights and address some of the topics in his recent eBook, Commercially Successful Cell Therapies: Navigating the Ultra Cold Chain Distribution Minefield. Attendees will have the opportunity to ask questions. Mr. O’Donnell’s eBook is available at blog.fisherbioservices.com. To learn more or register for the webinar, go to http://connect.fisherbioservices.com/webinar/cell_therapy_webinar_clinical_trials_commercialization

About Fisher BioServices

Fisher BioServices has 28 years of experience in biorepository/biobanking services, cold chain logistics, and related support services for health-related research. The company manages high value biological specimens, cell-based therapeutics, vaccines, tissues, and related data in support of both clinical and public health research; they store and distribute more than 170,000,000 samples in more than 20 facilities worldwide for government, academic, and pharmaceutical clients. Fisher BioServices is part of Thermo Fisher Scientific Inc., the world leader in serving science.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $13 billion, we have 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit http://www.thermofisher.com.

Read the full story at http://www.prweb.com/releases/FisherBioServices/CellTherapy/prweb11089099.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
2. Generex Secures Commitments for $3.6M Capital Raise
3. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
4. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
5. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
6. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
7. Vital Imaging Makes Greater Commitment into MRI Research
8. Gene Therapy - Technologies, Markets and Companies
9. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
10. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... ... for blood donations in South Texas and across the nation is growing. , But according ... donations are on the decline. In fact, donations across the country are at their lowest ... in the last four years alone. , There is no substitute for blood. , “We ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a leading independent ... Aurora, Ohio, has broken ground on a new building in Holly Springs, NC. ... this new location solidifies a commitment to business in the region. The new ...
(Date:5/20/2016)... ... , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, ... the disease. Surviving Mesothelioma has just posted an article on the new study. ... their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces parvulus, ...
(Date:5/19/2016)... ... 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, a ... Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 years ... preclinical and clinical safety programs. “We’ve seen significant demand for, and we are ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
Breaking Biology News(10 mins):